News & Financial Highlights >
Features Archive

The DNA Revolution
Fifty Years after Watson and Crick, the New Questions in Genetics - From NPR

BioWorld Reports from BIO's CEO Conference
Deal-Making Rules Changing; Pharma, Biotechs Shop Around
FDA Chief Outlines Strategy; Industry Still 'Upbeat, Tough'

Cytokine Blockers
- From Signals by Jennifer Van Brunt

News from the Future of Life Summit

• Day 3: Living to 1000? (Feb. 21, 2003)
• Day 2: Tough Questions, No Easy Answers (Feb. 21, 2003)
• Live from the Future of Life (Feb. 20, 2003)
• The Ghost of Old Doc Ricketts (Feb. 19, 2003)

Biotechs Scored 23 Product Approvals In 2002, Including 9 New Therapies
- From Signals by Jennifer Van Brunt

Biotech: Best Story Yet to Come
from BIO News February-March 2003 by Carl B. Feldbaum
Read More >

The Year of the Bear
- From Signals by Jennifer Van Brunt

It's a Personal Thing: The Rise of Information-Based Medicine
- From Biotechnology Investors' Forum (PDF) by Cormac Sheridan

E&Y: Biotech Reaches Globally For Financing And Opportunity
- From BIOWorld Online by Karen Pihl-Carey

Medicon Valley Developing R&D Capabilities, Attracting Attention
- From BIOWorld Online by Cormac Sheridan

New Nucleoside Analogue, Drug Combos Promising In Leukemia
- From BIOWorld Online by Randall Osborne

The Placebo Effect
Market forces, product difficulties and delays have driven down stock prices, dried up cash reserves and compelled many biotech firms to tighten their belts. - From Signals Magazine

Playing the game, for better...
An interview with Nasdaq vice chairman Alfred R. Berkeley III
- From Biotechnology Investors' Forum

Financing in a down market
'When will biotech come back?', and, 'what type of biotech companies will succeed?' and 'where do biotechs go for cash?'
- From Biotechnology Investors' Forum

Related Information BIO Hosts Industry's Largest Venture Event Adspeak: Small Private Company Seeks Venture Backing A VentureForum Profile: Inhibitex Prevails in a Changing Market BIO VentureForum Web site Press Coverage Impatient Investors Wonder When New Technologies Will Pay Off Biotech firms go prospecting for venture capital

Stocks Are Down, Financing Up (Sept. 2002)
This summer was like early 1999 all over again... the last time the Nasdaq Biotech Index slipped below 500.
Read More >